TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 12424783

Group type: EXPERIMENTAL
Intervention: Combined individual telephone and in-person group support and education for 13 months
Number of subjects: 125

Group type: COMPARATOR
Intervention: Telephone-only individual support and education for 13 months
Number of subjects: 125

Group type: COMPARATOR
Intervention: One-time mailed educational information
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 125
Study: 10915227

Group type: EXPERIMENTAL
Intervention: Cuff width:arm circumference ratio of 46.4%
Number of subjects: 50

Group type: COMPARATOR
Intervention: Standard 13cm-wide cuff
Number of subjects: 50
Study: 8652324

Group type: EXPERIMENTAL
Intervention: 4% human albumin (HA)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: 3.5% dextran 40 (Dxt 40)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: 6% hydroxyethylstarch 200 (HES)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: 6% dextran 60 (Dxt 60)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: modified fluid gelatin (Gel)
Number of subjects: 40
Study: 1647149

Group type: EXPERIMENTAL
Intervention: Cisplatin (80 mg/m2, day 1)/Etoposide (100 mg/m2, day 1, 3, 5) (PE)
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Cisplatin (80 mg/m2, day 1)/Etoposide (100 mg/m2, day 1, 3, 5)/Ifosfamide (2 g/m2, day 1, 2, 3) (PEI)
Number of subjects: 92
Study: 6395435

Group type: EXPERIMENTAL
Intervention: Desmopressin
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (no desmopressin)
Number of subjects: 30
Study: 12270864

Group type: EXPERIMENTAL
Intervention: Atorvastatin
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study: 29853320

Group type: EXPERIMENTAL
Intervention: Sunitinib
Number of subjects: 375
Study: 26537943

Group type: EXPERIMENTAL
Intervention: High-DHA diet (1% of total fatty acids)
Number of subjects: 104

Group type: COMPARATOR
Intervention: Standard-DHA diet (0.2-0.3% of total fatty acids as DHA)
Number of subjects: 104
Study: 24811095

Group type: EXPERIMENTAL
Intervention: Combined monitoring (ultrasound plus serum estradiol monitoring, UHM group)
Number of subjects: 416

Group type: COMPARATOR
Intervention: Ultrasound monitoring only (UM group)
Number of subjects: 416
Study: 22652942

Group type: EXPERIMENTAL
Intervention: Prednisolone, 60 mg/d for 5 days, tapered for 5 days
Number of subjects: 829
Study: 19451806

Group type: EXPERIMENTAL
Intervention: Statins (specifically ezetimibe/simvastatin)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Statins
Number of subjects: 0
Study: 17565287

Group type: EXPERIMENTAL
Intervention: Video Interaction Project (VIP)
Number of subjects: 99

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 99
Study: 16204002

Group type: EXPERIMENTAL
Intervention: Female patients (n=2050)
Number of subjects: 4626

Group type: COMPARATOR
Intervention: Male patients (n=2576)
Number of subjects: 4626

Group type: EXPERIMENTAL
Intervention: Severe leucopenia during chemotherapy
Number of subjects: 4626

Group type: EXPERIMENTAL
Intervention: Patients who developed severe leucopenia within the first two cycles of chemotherapy
Number of subjects: 4626
Study: 12352809

Group type: EXPERIMENTAL
Intervention: Birth dose of HepB
Number of subjects: 550

Group type: COMPARATOR
Intervention: No birth dose of HepB
Number of subjects: 550

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 550
Study: 10497976

Group type: EXPERIMENTAL
Intervention: Relatives of soldiers positive for cysticercosis and taeniasis markers
Number of subjects: 1000

Group type: EXPERIMENTAL
Intervention: Relatives of positive soldiers
Number of subjects: 1000

Group type: COMPARATOR
Intervention: Family members of the control group
Number of subjects: 1000

Group type: EXPERIMENTAL
Intervention: Soldiers
Number of subjects: 1000

Group type: EXPERIMENTAL
Intervention: Relatives
Number of subjects: 1000

Group type: EXPERIMENTAL
Intervention: Soldiers and relatives
Number of subjects: 1000
Study: 7843758

Group type: EXPERIMENTAL
Intervention: Amlodipine (10 mg)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Lisinopril (10 mg)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Amlodipine
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Lisinopril
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Amlodipine and Lisinopril
Number of subjects: 20
Study: 2236929

Group type: EXPERIMENTAL
Intervention: Beclomethasone dipropionate 500 micrograms daily
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Beclomethasone dipropionate 1,000 micrograms daily
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 406627

Group type: EXPERIMENTAL
Intervention: 10 mg methylphenidate
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 30 mg methylphenidate
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 45 mg methylphenidate (open trial)
Number of subjects: 12
Study: 30379568

Group type: EXPERIMENTAL
Intervention: Avelumab maintenance therapy
Number of subjects: 499

Group type: COMPARATOR
Intervention: Continuation of first-line chemotherapy
Number of subjects: 499
Study: 28802596

Group type: EXPERIMENTAL
Intervention: Early-phase remote ischemic preconditioning (ERIPC)
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Late-phase remote ischemic preconditioning (LRIPC)
Number of subjects: 65

Group type: COMPARATOR
Intervention: Control group (CON)
Number of subjects: 65
Study: 24638908

Group type: EXPERIMENTAL
Intervention: Daily supplementation with long‐chain ω‐3 polyunsaturated fatty acids (350 mg DHA + 650 mg EPA)
Number of subjects: 4203

Group type: EXPERIMENTAL
Intervention: Daily supplementation with lutein + zeaxanthin (10 mg lutein + 2 mg zeaxanthin)
Number of subjects: 4203

Group type: EXPERIMENTAL
Intervention: Combination of long‐chain ω‐3 fatty acids and lutein + zeaxanthin
Number of subjects: 4203

Group type: COMPARATOR
Intervention: Matching placebos
Number of subjects: 4203
Study: 23651231

Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (800 mg/day)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study: 20175973

Group type: EXPERIMENTAL
Intervention: Hip strengthening (physiotherapist-supervised home exercise program targeting hip abductor and adductor muscles for 12 weeks)
Number of subjects: 89

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: Hip strengthening
Number of subjects: 89
Study: 18359332

Group type: EXPERIMENTAL
Intervention: Naproxen
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tiaprofenic acid
Number of subjects: 0

Group type: COMPARATOR
Intervention: Ibuprofen
Number of subjects: 0

Group type: COMPARATOR
Intervention: Indomethacin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sulindac
Number of subjects: 0

Group type: COMPARATOR
Intervention: Celecoxib
Number of subjects: 0
Study: 16781230

Group type: EXPERIMENTAL
Intervention: Abciximab
Number of subjects: 1885

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1885
Study: 12680858

Group type: EXPERIMENTAL
Intervention: Fish oil supplementation (3.7 g n-3 PUFA/day)
Number of subjects: 83

Group type: COMPARATOR
Intervention: Placebo supplementation
Number of subjects: 83
Study: 10887922

Group type: EXPERIMENTAL
Intervention: 0.01% all‐trans‐retinoic acid (tretinoin) ophthalmic emulsion
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study: 9197524

Group type: EXPERIMENTAL
Intervention: Vitamin C supplementation (50 or 500 mg/day) for 5 years
Number of subjects: 397

Group type: COMPARATOR
Intervention: Beta-carotene supplementation (0 or 15 mg/day) for 5 years (discontinued after initial recruitment)
Number of subjects: 397
Study: 8110565

Group type: EXPERIMENTAL
Intervention: Extradural morphine 0.75 microgram kg‐1 with an additional dose administered 24 h later (group M)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Extradural fentanyl 2 micrograms kg‐1 followed by continuous extradural infusion of fentanyl 5 micrograms kg‐1 day‐1 (group F)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Continuous extradural infusion of fentanyl 5 micrograms kg‐1 day‐1
Number of subjects: 30
Study: 3050510

Group type: EXPERIMENTAL
Intervention: Isaxonine
Number of subjects: 20
Study: 31045852

Group type: EXPERIMENTAL
Intervention: Prenatal exposure to 1,3-butadiene during the second trimester
Number of subjects: 243

Group type: EXPERIMENTAL
Intervention: Prenatal exposure to meta/para-xylene during the second trimester
Number of subjects: 243

Group type: EXPERIMENTAL
Intervention: Prenatal exposure to traffic-related air toxics
Number of subjects: 243
Study: 28427544

Group type: EXPERIMENTAL
Intervention: WBVT (whole-body vibration training)
Number of subjects: 74

Group type: COMPARATOR
Intervention: Control (squat training without WBVT)
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: WBVT
Number of subjects: 74

Group type: COMPARATOR
Intervention: Control
Number of subjects: 74
Study: 24412895

Group type: EXPERIMENTAL
Intervention: Methotrexate and intra-articular glucocorticosteroid injections with adalimumab
Number of subjects: 85

Group type: COMPARATOR
Intervention: Methotrexate and intra-articular glucocorticosteroid injections with placebo
Number of subjects: 85
Study: 24259786

Group type: EXPERIMENTAL
Intervention: Stomatognathic alignment exercise
Number of subjects: 14

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 14
Study: 21416146

Group type: EXPERIMENTAL
Intervention: EE estimated by individual equation (EE(mag‐Val‐INDIV))
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: EE estimated by group equation (EE(mag‐val‐GROUP))
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Group equation (EE(mag‐val‐GROUP))
Number of subjects: 11
Study: 19273714

Group type: EXPERIMENTAL
Intervention: Gemcitabine-docetaxel (GD)
Number of subjects: 305

Group type: COMPARATOR
Intervention: Capecitabine-docetaxel (CD)
Number of subjects: 305
Study: 17907739

Group type: EXPERIMENTAL
Intervention: Alcohol-based hand sanitizer
Number of subjects: 383

Group type: COMPARATOR
Intervention: Soap and water (hand washing)
Number of subjects: 383
Study: 15147076

Group type: EXPERIMENTAL
Intervention: STRESSEN
Number of subjects: 20

Group type: COMPARATOR
Intervention: arginine glutamate
Number of subjects: 20
Study: 11500582

Group type: EXPERIMENTAL
Intervention: Bi-atrial pacing (BAP)
Number of subjects: 118

Group type: COMPARATOR
Intervention: No atrial pacing (NAP)
Number of subjects: 118
Study: 8831082

Group type: EXPERIMENTAL
Intervention: Prophylactic fresh frozen plasma (20 ml/kg followed by 10 ml/kg after 24 h)
Number of subjects: 776

Group type: EXPERIMENTAL
Intervention: Inert gelatin plasma substitute (Gelofusine)
Number of subjects: 776

Group type: COMPARATOR
Intervention: Control management with a maintenance infusion of 10% dextrose
Number of subjects: 776

Group type: EXPERIMENTAL
Intervention: Prophylactic fresh frozen plasma
Number of subjects: 776
Study: 1282183

Group type: EXPERIMENTAL
Intervention: 40 mg nicorandil
Number of subjects: 38

Group type: COMPARATOR
Intervention: 0.8 mg nitroglycerin
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: 10 or 20 mg nicorandil
Number of subjects: 38

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study: 4040500

Group type: EXPERIMENTAL
Intervention: OKY‐1581 (thromboxane A2 synthetase inhibitor); 2-3 micrograms/kg per min for 48 hours
Number of subjects: 55

Group type: COMPARATOR
Intervention: Control group (no treatment with OKY‐1581)
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: OKY‐1581 treatment
Number of subjects: 55
Study: 31142344

Group type: EXPERIMENTAL
Intervention: Postpartum contraceptive counseling and immediate postpartum intra-uterine device (PPIUD) insertion services
Number of subjects: 75587

Group type: EXPERIMENTAL
Intervention: Counseling due to the intervention
Number of subjects: 75587
Study: 29474291

Group type: EXPERIMENTAL
Intervention: Icon™ reusable underwear
Number of subjects: 70

Group type: COMPARATOR
Intervention: Disposable pads
Number of subjects: 70
Study: 26175459

Group type: EXPERIMENTAL
Intervention: Didactic curriculum in two 3-hour sessions
Number of subjects: 1378

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 1378
Study: 24685536

Group type: EXPERIMENTAL
Intervention: Computerised bias modification positive appraisal training (CBM)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Therapist-delivered cognitive behavioural therapy session (CB-Education)
Number of subjects: 60

Group type: COMPARATOR
Intervention: No intervention monitoring control condition (Control)
Number of subjects: 60
Study: 23103036

Group type: EXPERIMENTAL
Intervention: Radial access
Number of subjects: 7021

Group type: COMPARATOR
Intervention: Femoral access
Number of subjects: 7021
Study: 19435959

Group type: EXPERIMENTAL
Intervention: Fenofibrate
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: Fenofibrate + Metformin
Number of subjects: 128

Group type: COMPARATOR
Intervention: Lifestyle intervention
Number of subjects: 128
Study: 17898698

Group type: EXPERIMENTAL
Intervention: Estimated GFR combining plasma creatinine (Pcr) and cystatin C (cysC) measurements
Number of subjects: 567

Group type: COMPARATOR
Intervention: Modified MDRD equation for Chinese patients
Number of subjects: 567

Group type: COMPARATOR
Intervention: Estimate combining cysC and modified MDRD calculations
Number of subjects: 567

Group type: COMPARATOR
Intervention: Equation based solely on cystatin C (cysC)
Number of subjects: 567
Study: 15151712

Group type: EXPERIMENTAL
Intervention: Human Menopausal Gonadotrophin (HMG)
Number of subjects: 280

Group type: COMPARATOR
Intervention: Recombinant FSH (rFSH)
Number of subjects: 280

Group type: EXPERIMENTAL
Intervention: Conception cycles
Number of subjects: 280

Group type: COMPARATOR
Intervention: Non-conception cycles
Number of subjects: 280
Study: 11685031

Group type: EXPERIMENTAL
Intervention: Erythromycin (1 mg/kg every 8 hours for 14 days)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Control (H2-receptor antagonists and gastrokinetic drugs)
Number of subjects: 31
Study: 9699091

Group type: EXPERIMENTAL
Intervention: CWT 3 days/week (n = 15)
Number of subjects: 27

Group type: COMPARATOR
Intervention: No formal exercise (control) (n = 12)
Number of subjects: 27
Study: 10411814

Group type: EXPERIMENTAL
Intervention: Couple testing
Number of subjects: 358

Group type: COMPARATOR
Intervention: Two-step testing
Number of subjects: 358
Study: 2239303

Group type: EXPERIMENTAL
Intervention: VP-16 alone
Number of subjects: 116

Group type: COMPARATOR
Intervention: VP-16 combined with other anti-tumor agents
Number of subjects: 116
Study: 657893

Group type: EXPERIMENTAL
Intervention: Training condition (visual-spatial disembedding training)
Number of subjects: 93

Group type: COMPARATOR
Intervention: Control condition (no training)
Number of subjects: 93
Study: 31505082

Group type: EXPERIMENTAL
Intervention: Duloxetine (exact dosage not specified)
Number of subjects: 1536

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1536

Group type: EXPERIMENTAL
Intervention: Duloxetine and Placebo (combined analysis)
Number of subjects: 1536
Study: 30801948

Group type: EXPERIMENTAL
Intervention: IVF (In Vitro Fertilisation)
Number of subjects: 6191

Group type: EXPERIMENTAL
Intervention: IVF-AO (In Vitro Fertilisation with Autologous Oocytes)
Number of subjects: 6191

Group type: EXPERIMENTAL
Intervention: IVF-OD (In Vitro Fertilisation with Oocyte Donation)
Number of subjects: 6191

Group type: EXPERIMENTAL
Intervention: Multiple pregnancy as an intermediate factor
Number of subjects: 6191
Study: 28197680

Group type: EXPERIMENTAL
Intervention: Condolence letter
Number of subjects: 242

Group type: COMPARATOR
Intervention: No condolence letter
Number of subjects: 242
Study: 25772750

Group type: EXPERIMENTAL
Intervention: 3D TV watching
Number of subjects: 72

Group type: COMPARATOR
Intervention: 2D TV watching
Number of subjects: 72
Study: 24026162

Group type: EXPERIMENTAL
Intervention: Thoracolumbosacral orthosis
Number of subjects: 0

Group type: COMPARATOR
Intervention: Watchful waiting
Number of subjects: 0
Study: 22021867

Group type: EXPERIMENTAL
Intervention: Comprehensive accreditation intervention implemented over two and a half winter sporting seasons, which includes multiple elements designed to decrease alcohol supply, cease provision of cheap alcohol, increase availability of non-alcoholic beverages, remove high alcohol drinks, and cease drinking games.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Printed materials on topics unrelated to alcohol (Control group).
Number of subjects: 0
Study: 19267963

Group type: EXPERIMENTAL
Intervention: Matched-taper single-cone obturation
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Lateral condensation obturation
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Thermafil obturation
Number of subjects: 66
Study: 17112804

Group type: EXPERIMENTAL
Intervention: Ezetimibe (20 mg orally)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Ezetimibe glucuronide (after rifampin coadministration)
Number of subjects: 8
Study: 14678952

Group type: EXPERIMENTAL
Intervention: IDPN + exercise
Number of subjects: 6

Group type: COMPARATOR
Intervention: IDPN only
Number of subjects: 6
Study: 11248608

Group type: EXPERIMENTAL
Intervention: Tolterodine ER 4 mg once daily
Number of subjects: 1529

Group type: EXPERIMENTAL
Intervention: Tolterodine IR 2 mg twice daily
Number of subjects: 1529

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1529

Group type: EXPERIMENTAL
Intervention: Tolterodine ER 4 mg once daily and Tolterodine IR 2 mg twice daily
Number of subjects: 1529
Study: 9227717

Group type: EXPERIMENTAL
Intervention: Pranlukast, 450 mg twice daily
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 8039526

Group type: EXPERIMENTAL
Intervention: Oral antidiabetic drugs
Number of subjects: 454

Group type: EXPERIMENTAL
Intervention: Insulin treatment
Number of subjects: 454

Group type: EXPERIMENTAL
Intervention: Antidiabetic drugs
Number of subjects: 454

Group type: EXPERIMENTAL
Intervention: Oral drugs
Number of subjects: 454

Group type: EXPERIMENTAL
Intervention: Active approach to pharmacological treatment
Number of subjects: 454

Group type: EXPERIMENTAL
Intervention: Metabolic control
Number of subjects: 454
Study: 3583495

Group type: EXPERIMENTAL
Intervention: Clomipramine
Number of subjects: 40

Group type: COMPARATOR
Intervention: Pentazocine
Number of subjects: 40
Study: 29567435

Group type: EXPERIMENTAL
Intervention: Piezotome II and Piezotome SOLO M+ with a piezotome‐adapted 3‐dimensional curved osteotomy surgical protocol
Number of subjects: 48

Group type: COMPARATOR
Intervention: Traditional sliding genioplasty protocol
Number of subjects: 48
Study: 28302271

Group type: EXPERIMENTAL
Intervention: Risk stratification model for 30-day heart failure readmission
Number of subjects: 1475

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 1475
Study: 25072666

Group type: EXPERIMENTAL
Intervention: Fundamental movement training (4 weeks, 4 × 30-minute sessions per week)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Generic multisport activity (control group)
Number of subjects: 22
Study: 22943848

Group type: EXPERIMENTAL
Intervention: Electrically Heated Cigarette Smoking System (EHCSS) series-K6 cigarette
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional lit-end cigarettes (CC)
Number of subjects: 0
Study: 21099596

Group type: EXPERIMENTAL
Intervention: Home-based testing (swabs mailed to the participant's home)
Number of subjects: 558

Group type: COMPARATOR
Intervention: Clinic-based testing
Number of subjects: 558
Study: 18498913

Group type: EXPERIMENTAL
Intervention: Single-dose memantine 5 mg
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Single-dose memantine 10 mg
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Single-dose memantine 20 mg
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Multiple-dose memantine 5 mg once daily for 14 days
Number of subjects: 40
Study: 15941893

Group type: EXPERIMENTAL
Intervention: Glutamine supplementation (0.3 g . kg(‐1) . d(‐1))
Number of subjects: 102

Group type: COMPARATOR
Intervention: Control supplementation (alanine)
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Glutamine supplementation
Number of subjects: 102

Group type: COMPARATOR
Intervention: Control supplementation
Number of subjects: 102
Study: 12906063

Group type: EXPERIMENTAL
Intervention: Bifidobacterium milk fermented with B. longum strain BL1
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Low-fat drinking yogurt with B. longum strain BL1 (B-group)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Low-fat drinking yogurt with ordinary yogurt starters (P-group)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Milk fermented with mixed culture of ordinary yogurt starters (SL)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Acid milk (control)
Number of subjects: 32
Study: 10562579

Group type: EXPERIMENTAL
Intervention: Sulindac 150 mg orally twice a day for three months (n=10)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo (n=11)
Number of subjects: 21
Study: 8712447

Group type: EXPERIMENTAL
Intervention: Intrathecal neostigmine (50, 100, or 200 micrograms in D5NS)
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Epidural clonidine (targeted to 50, 100, 200, or 400 ng/ml)
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Combination of neostigmine and clonidine
Number of subjects: 58

Group type: COMPARATOR
Intervention: D5NS (control group)
Number of subjects: 58
Study: 1910342

Group type: EXPERIMENTAL
Intervention: FCH-free, NTG-containing spray (0.8 mg NTG)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: FCH- and NTG-containing spray (0.8 mg NTG)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo (FCH- and NTG-free spray, 2 puffs)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: NT/NR comparison
Number of subjects: 15
Study: 6351988

Group type: EXPERIMENTAL
Intervention: Estramustine phosphate
Number of subjects: 0

Group type: COMPARATOR
Intervention: Stilbestrol
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 0
Study: 31876707

Group type: EXPERIMENTAL
Intervention: Femtosecond laser-assisted cataract surgery (FLACS)
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Microincision cataract surgery (MICS)
Number of subjects: 87

Group type: COMPARATOR
Intervention: Conventional phacoemulsification surgery (CPS)
Number of subjects: 87
Study: 26602701

Group type: EXPERIMENTAL
Intervention: Culturally adapted exercise program
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: Standard exercise intervention
Number of subjects: 89

Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 89